ArticleScientific reports2022
Neolignans isolated from Saururus cernuus L. (Saururaceae) exhibit efficacy against Schistosoma mansoni.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- 4‑ACS omega · 2026Article
- ExploringIn silico pharmacology · 2026Article
- Acetylene Acetogenin fromACS omega · 2025Article
- Discovery of clocinizine as a potential oral drug against Schistosoma mansoni infection.Scientific reports · 2025Article
- Benzoxanthenone Lignans Related to Carpanone, Polemanone, and Sauchinone: Natural Origin, Chemical Syntheses, and Pharmacological Properties.Molecules (Basel, Switzerland) · 2025Review
- Anthelmintic Potential of Conjugated Long-Chain Fatty Acids Isolated from the Bioluminescent MushroomJournal of natural products · 2025Article
- Anthelmintic activity of 1,10-phenanthroline-5,6-dione-based metallodrugs.Scientific reports · 2025Article
- Atomic force microscopy reveals morphological and mechanical properties of schistosoma mansoni tegument.Scientific reports · 2024Article
- EDBD-3,6-Epidioxy-1,10-Bisaboladiene-An Endoperoxide Sesquiterpene Obtained fromAntibiotics (Basel, Switzerland) · 2024Article
- Pharmacophore Virtual Screening Identifies Riboflavin as an Inhibitor of the Schistosome Cathepsin B1 Protease with Antiparasitic Activity.ACS omega · 2024Article
- The 3D pharmacophore modeling to explore new antischistosomal agents among US FDA approved drugs.Future medicinal chemistry · 2024Article
- Targeting the Schistosoma mansoni nutritional mechanisms to design new antischistosomal compounds.Scientific reports · 2023Article
- Evaluating the Antischistosomal Activity of Dehydrodieugenol B and Its Methyl Ether Isolated fromACS omega · 2023Article
- The Existing Drug Nifuroxazide as an Antischistosomal Agent:Microbiology spectrum · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 2 countries.
Funding
Abstract
Schistosomiasis, a parasitic disease caused by the blood fluke of the genus Schistosoma, affects over 230 million people, especially in developing countries. Despite the significant economic and public health consequences, only one drug is currently available for treatment of schistosomiasis, praziquantel. Thus, there is an urgent demand for new anthelmintic agents. Based on our continuous studies involving the chemical prospection of floristic biodiversity aiming to discover new bioactive compounds, this work reports the in vitro antiparasitic activity against Schistosoma mansoni adult worms of neolignans threo-austrobailignan-6 and verrucosin, both isolated from Saururus cernuus L. (Saururaceae). These neolignans showed a significant in vitro schistosomicidal activity, with EC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.